SCHEMBL6209907

SCHEMBL6209907

Clc1cnc(Nc2ccc3[nH]ncc3c2)nc1NCc1ccccn1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 11/20 0.75
PTK2B Q14289 6/20 0.75
KDR P35968 6/20 0.54
WEE1 P30291 4/20 0.54
ALK Q9UM73 4/20 0.54
ROCK1 Q13464 3/20 0.54
AURKA O14965 3/20 0.54
DAPK3 O43293 3/20 0.54
JAK2 O60674 3/20 0.54
PRKD3 O94806 3/20 0.54
MAP4K4 O95819 3/20 0.54
PAK4 O96013 3/20 0.54
LCK P06239 3/20 0.54
FYN P06241 3/20 0.54
CSF1R P07333 3/20 0.54
RET P07949 3/20 0.54
IGF1R P08069 3/20 0.54
FGFR1 P11362 3/20 0.54
PDGFRA P16234 3/20 0.54
PRKACA P17612 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6211361 0.92 PTK2 (0.64) PTK2PTK2BKDRWEE1ALK
SCHEMBL6214284 0.90 PTK2 (0.61) PTK2PTK2BKDRWEE1ALK
SCHEMBL6212988 0.88 PTK2 (0.75) PTK2PTK2BKDRIGF1RFGFR1
SCHEMBL6213528 0.88 PTK2 (0.78) PTK2PTK2BKDRROCK1DAPK3
SCHEMBL6241400 0.88 PTK2 (0.75) PTK2PTK2BKDRWEE1ALK
SCHEMBL6257378 0.85 PTK2 (1.00) PTK2PTK2BWEE1ALKROCK2
SCHEMBL6213524 0.83 PTK2 (0.67) PTK2PTK2BKDRALKROCK1
SCHEMBL6259622 0.82 PTK2 (0.67) PTK2PTK2BKDRWEE1ALK
SCHEMBL6768877 0.81 PTK2 (0.64) PTK2PTK2BROCK1JAK2ROCK2
SCHEMBL6213429 0.81 PTK2 (0.65) PTK2PTK2BKDRWEE1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885KDR 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.